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Abstract
Purpose: Endothelin-1 (ET) is an important molecule in vascular physiology. After an acute stimulation with ET,
vessels are to some extent temporarily refractory to further stimulation. However, few details are known about
this phenomenon. The aim of our study was to verify the existence of refractoriness in ophthalmic ciliary arteries
and, if present, to analyze its time course.
Methods: Twenty freshly isolated porcine ciliary arteries were placed in a myograph system to measure iso-
metric forces. Each vessel was stimulated with 10 - 7 M ET twice. The experiment was performed in 5 groups of
vessels, which differed in the time interval between the initial and the second stimulation with ET. The intervals
were 15min, 30min, 1 h, 2 h, and 4 h, respectively.
Results: The vasoconstrictive response to re-exposure to ET was time-dependently reduced. The response was
lowest after 15min (22% of baseline response), and then the sensitivity slowly recovered and was finally normal
again after 4 h.
Conclusions: Our experiment with isolated porcine ophthalmic ciliary arteries revealed a refractoriness phase to
ET after an acute stimulation with ET. This refractoriness was transient and disappeared after 4 h. The lowest
response was observed in the group of vessels re-exposed 15min after the first stimulation.
Introduction
Endothelin, identified in 1988 by Yanagisawa et al.,
1 is
one of the strongest known endogenous vasoconstric-
tors. The predominant isoform in the endothelin family is
endothelin-1 (ET). Under physiological conditions, ET is
mainly synthesized by vascular endothelial cells. However,
in hypoxia or other pathological conditions, ET can also be
produced by other cells.2–4 In humans, the effects of ET are
mediated by 2 types of ET receptors: the type-A receptor
(ETA) and the type-B receptor (ETB). ETA receptors are found
on vascular smooth muscle cells, and their stimulation leads
to marked and sustained vasoconstriction by increasing cy-
toplasmatic calcium. ETB receptors can be found on both
endothelial cells and smooth muscle cells. ETB receptors on
endothelial cells mediate the release of vasodilatory nitric
oxide and/or prostacyclin; however, stimulation of ETB re-
ceptors on smooth muscle cells provokes vasoconstriction.5
Together with other vasoactive molecules and the auto-
nomic nervous system, ET regulates vascular tone. Several
factors modulate the production of ET, including shear
stress,6 hypoxia-inducible factor-1-alpha,7 angiotensin II,8,9
adrenaline,10 inflammatory cytokines11,12 and others.
It is obvious that any malfunction in this system locally or
systemically can have pathophysiologic implications, and a
relative increase in ET can lead to vasoconstriction or even
vasospasm. Indeed, ET raises blood pressure13 and induces
vascular and myocardial hypertrophy,14,15 both contributors
to increased cardiovascular morbidity and mortality.16 ET
has been shown to be involved in the pathogenesis of many
diseases.4
In the eye, the regulation of blood flow is different in
distinct vascular beds. Retinal circulation is mainly regulated
by endothelium-derived vasoactive factors, while choroid
circulation is predominantly regulated by the autonomic
nerve system.17 Optic nerve head circulation is, like that of
the retina, regulated by endothelial cells, but it is also under
the direct influence of circulating hormones (including ET).
These circulating hormones diffuse from fenestrated capil-
laries of the choroid into the optic nerve head and reach the
vascular smooth muscle cells directly, by-passing the blood-
retinal barrier.17,18 This is the reason why an increased level
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of ET in the circulating blood (as can be observed in many
different autoimmune diseases such as multiple sclerosis)
has a major effect on optic nerve head circulation but no
or only a minimal effect on retinal or brain circulation. An
increased level of ET seems to be implicated in the patho-
genesis of many ocular diseases, particularly retinal vein
occlusion,19,20 glaucoma,21 diabetic retinopathy,22 and giant
cell arteritis.23
Although ET obviously plays an important role, many
basic aspects of its function are still poorly understood, in-
cluding the question of the dose-response relationship. An
acute rise in ET concentration may have a completely dif-
ferent effect from a chronic increase.
The mode of action of ET is different from other vaso-
constrictors like adrenaline or angiotensin II. Once ET binds
to its receptor, it will barely dissociate again.24 After binding,
ET is rapidly internalized together with its receptor.25 Such
an internalization of the ET-ET receptor complex influences
local ET concentration to some extent and has a major impact
on receptor density and thus ET sensitivity.
Although tachyphylaxis with ET was already observed in
rat aortic rings in 1993,26 this phenomenon was not taken
into account in later in vitro and ex vivo study designs. On the
contrary, in many studies investigating the effect of ET and
its blockers on vascular function, vessels were exposed to
stepwise incremental concentrations of ET. If the vasculature
is refractory to ET, the results of such studies should be in-
terpreted with caution, especially when high concentrations
of ET are studied. Information about refractoriness is of rel-
evance for physiology, pathophysiology, and pharmacology,
especially in light of the fact that ET and its receptors are
promising targets for future drugs.
The purpose of the present study was a) to test whether
refractoriness indeed exists in ocular vessels and b) to esti-
mate its time course. By working on isolated vessels, the
effect of ET is separated from the influence of other regula-
tory systems, like the autonomic nerve system or neurovas-
cular coupling.
Methods
Preparation of vessels
In adherence with the Association for Research in Vision
and Ophthalmology (ARVO) Statement for Use of Animals
in Ophthalmic and Vision Research, porcine eyes with sur-
rounding tissue were obtained from a local slaughterhouse
immediately after death and transported in cold modified
Krebs-Ringer solution (NaCl 118mMol, KCl 4.7mMol,
KH2PO4 1.2mMol, MgSO4 1.2mMol, NaHCO3 25mMol,
EDTA 0.026mMol, CaCl2 2.5mMol, Glucose 11.1mMol).
Ciliary arteries were dissected under a microscope (Wild
M3C; Wild Heerbrugg AG) and cut into 2-mm segments.
Arterial rings were mounted in specially designed organ
chambers for small vessels (myograph system27). In an organ
chamber, two 40-mm tungsten wires were passed through the
vessel’s lumen and attached to a force transducer for iso-
metric force measurements (Multi Wire Myograph System
610M; Danish Myo Technology). Mounted vessels were im-
mersed in the myographs’ organ chambers filled with Krebs-
Ringer bicarbonate solution (37C; 95% O2, 5% CO2) and
stretched in a stepwise manner until the optimum passive
tension was reached. The optimum passive tension was de-
fined as the level of vascular wall tension at which contrac-
tions to 100mM potassium chloride (KCl) became maximal.
The vessels were then washed out with modified Krebs-
Ringer solution before the following experimental protocols
were conducted.
Experimental protocols
Each of 20 ciliary arteries was stimulated with ET twice.
Quiescent vessels were first exposed to 10- 7 M ET, then
washed out with modified Krebs-Ringer solution, and then
exposed to 10 - 7 M ET again. Five series of experiments were
performed, which differed in the time interval between the
initial and the second stimulation with ET: 15min, 30min,
1 h, 2 h, and 4 h, respectively. At the end of each experiment,
vessels were exposed to 100mM KCl to establish that they
were still responsive to vasoconstrictor agents. In each series
of experiments, 4 porcine ciliary arteries of 4 animals were
used (one vessel per experiment).
Drugs and statistical analyses
ET was purchased from Sigma-Aldrich Chemie GmbH. It
was dissolved in distilled water. Concentrations are ex-
pressed as final molar concentrations in the organ chambers.
Results are given as ratio ETsec/ETini, where ETsec repre-
sents the response to the second stimulation with ET and
ETini represents the response to the initial stimulation with
ET. To explore the ratio ETsec/ETini, descriptive statistics
including mean and standard deviation were calculated. A
graphical description using boxplots was assessed. To com-
pare ETsec/ETini across all time points, a linear regression
model was performed. All ratios were compared to 1. Results
are also expressed as differences of means to 1 for each time
point. Standard errors (SEs) and corresponding P values are
also reported. P values and SEs were adjusted for multiple
comparisons using the method of Dunnett.28 A P value < 0.05
was considered to be statistically significant. All analyses
were done using the statistical package R version 12.2.29
Results
The vasoconstrictive response to re-exposure to ET was
time-dependently reduced in comparison to the initial ET
stimulation (Fig. 1, Table 1). The vasoconstrictive response to
the first exposure to ET was arbitrarily defined as 1U.
15min, 30min, 1 h, and 2h after initial stimulation, the va-
soconstrictive response to the second stimulation with ET
was significantly lower than 1. The response was lowest at
the 15min time point with a mean response of 0.22 (ie, 22%
of baseline response) and then slowly recovered to 0.29, 0.63,
and 0.80 for the 30-min, 1-h, and 2-h time points, respec-
tively. At the 4-h time point, the response reached an average
of 0.9, a value that was no longer significantly different from
the baseline value of 1.
At the end of the experiments, all vessels were still com-
pletely responsive to 100mM KCl.
Discussion
The present study demonstrateted that (1) after an acute
stimulation with ET, vascular smooth muscle cells in the
porcine ciliary arteries were temporarily partly refractory
to further stimulation and (2) this refractory effect was
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strongest after 15min and then attenuated and finally dis-
appeared after 4 h.
After ET was discovered, Hirata et al. reported that the
ET-induced increase in cytosolic free Ca2 + levels is reversibly
absent or attenuated in ET-pretreated cultured cells.30 Fur-
thermore, a decreased vasoconstrictive effect after repeated
ET administration was observed in rat aortic rings26; how-
ever, in this study, the time course of this phenomenon was
not investigated. Desensitization to the effect of ET was also
observed in rat mesenteric arterial smooth muscle cells,31 in
isolated guinea-pig ileum,32 and in human small bronchi.33
Concerning in vivo studies, however, the literature on the
refractory phenomenon of ET is ambiguous. In anesthetized
rats, the rapid development of desensitization to the hypo-
tensive effects of ET was observed when repeated intrave-
nous bolus injections of this peptide were given.34 However,
in the same study, the vasoconstrictive effects of ET did not
undergo a fading phenomenon upon successive adminis-
trations of ET in pithed rats. This discrepancy between ex
vivo and in vivo studies may be due to the different doses and
therefore concentrations applied. But it is also possible that
vessels denervated and isolated from their surroundings
behave differently.
The observation that repeated stimulation of receptors by
their agonists can lead to transient refractoriness is not spe-
cific for ET. Such phenomena are particularly observed when
receptors are stimulated with high doses and may protect
cells from overstimulation and potential damage. The exact
mechanism of refractoriness to ET is not known. One im-
portant component might be the internalization of the ET-
ET-receptor complex. These complexes are rapidly internal-
ized by receptor-mediated endocytosis. After internalization,
ETA and ETB receptors are targeted to different intracellular
fates. Whereas the ETA receptor follows the recycling path-
way through the pericentriolar recycling compartment and
then reappears at the plasma membrane,35,36 the ETB recep-
tor is directed to lysosomes for degradation.35 Therefore, a
longer lasting signaling response can be achieved upon ETA
receptor stimulation.35 The cytoplasmic carboxyl-terminal
tail of the ETA receptor is responsible for targeting this pep-
tide to the recycling pathway.35 This motif is lacking in the
carboxyl-terminal region of the ETB receptor, facilitating a
divergent endocytic sorting of the ETA receptor and ETB re-
ceptor.37 The time of internalization until reappearance of the
receptors may correspond to the refractoriness.
However, receptor recycling may not be the only regula-
tory mechanism accountable for the refractory phenomenon
of ET. ET receptors belong to the G protein-coupled receptors
(GPCRs) family.38 GPCR signaling receives negative feed-
back by G protein-coupled receptor kinases (GRK). ET sig-
naling in arterial smooth muscle is tightly regulated by
GRK2.31 The inhibition of GRK2 reduces the extent of ETA
receptor desensitization, thus indicating that GRK2 may play
an important role in the ET refractory phenomenon.
In addition, we cannot exclude that a certain component of
the refractoriness is immanent to the experimental set-up.
The vasoconstrictive response to the second ET stimulation
might be reduced due to the fact that the resting tension at
the time point of the second ET stimulation has not returned
to the baseline levels yet. This, however, cannot explain the
entire refractoriness observed in our study for the following
reason: although the resting tension was still increased at the
moment of the second ET stimulation, the total response
(active response + resting tension) after the second ET stim-
ulation was less than after the initial ET stimulation.
The observed refractoriness is most likely multifactorial.
The purpose of the present study was to test the existence of
refractoriness in an experimental set-up commonly used,
particularly in drug studies. In such ex vivo experiments
using a myograph system, vessels are often exposed to
stepwise incremental concentrations of ET. Further studies
are needed to explain the exact mechanism of this temporary
FIG. 1. Twenty isolated ciliary arteries were stimulated
with 10- 7 M endothelin-1 (ET) twice, on baseline condition
and after a latency shown on the x-axis. The response to the
initial ET stimulation (baseline) was arbitrarily defined as 1.
The response to the second ET stimulation was expressed as
the ratio ETsec/ETini and shown on the y-axis. (N = 4 vessels
for each time point). Results are presented as box plots.
ETini = vasoconstrictive response to the initial stimulation
with ET-1 (baseline value); ETsec = vasoconstrictive response
to the second stimulation with ET-1 (re-exposure); Time =
time interval between the initial and the second stimulation
with ET-1.
Table 1. Vasoconstrictive Response to the Second
Stimulation with ET-1 in Relation to Baseline
(ETini, Defined as 1.0) When Porcine Ciliary
Arteries Were Re-exposed to ET-1
Ratio ETsec/ETiniTime interval
between baseline
and re-exposure Mean response SD P value
15min 0.22 0.11 P < 0.001
30min 0.29 0.09 P < 0.001
1 h 0.63 0.17 P < 0.001
2 h 0.80 0.08 P < 0.007
4 h 0.90 0.15 P = 0.13
Results are presented as ratio ETsec/ETini (mean, SD, and P value)
for each time point.
(ETini =vasoconstrictive response to the initial stimulation with
ET-1; ETsec =vasoconstrictive response to the second stimulation
with ET-1)
ET, endothelin-1; SD, standard deviation.
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desensitization of vascular smooth muscle cells to ET and to
distinguish between the roles of the ETA and ETB receptors.
What about the clinical implication of these findings? The
level of ET in the circulating blood is increased in many
diseases, including ocular diseases such as retinal vein oc-
clusion,19,20 diabetic retinopathy,22 giant cell arteritis,23 and
retinitis pigmentosa.39 Less is known about the extravascular
ET concentration. It is increased, for example, in the aqueous
humor of glaucoma patients40 and is present in epiretinal
membranes.41 Even less is known about the time course of
ET concentrations in tissues such as retina. However, acute
hypoxia—as it occurs in many clinical conditions—stimu-
lates ET expression locally, and without refractoriness, it can
lead to a vicious circle.
Furthermore, information about refractoriness to ET is for
sure of relevance for pharmacological vascular research. ET
and its receptors are promising targets for future drugs.
What is the relationship between the concentration of ET
used in our study and biological concentrations? The ma-
jority of ET produced in the endothelial cells is secreted ab-
luminally, and only a small part is released into the lumen of
the vessels. The resulting ET concentration in the circulating
blood is in the range of pg/mL (1 pg/mL ET-1= 0.4 · 10 - 12
M), whereas in the vascular wall, it is probably in the range
of ng/mL42 (1 ng = 0.4 · 10 - 9 M). However, little is known
about the actual concentration in the extracellular space,
between endothelial cells and smooth muscle cells. Even
less is known about the corresponding concentration in the
tissues under pathological conditions. Indeed, the concen-
tration of ET used in our study may be higher than physio-
logical concentration; however, it might be in the range
reached under pathological conditions. We have chosen an
ET concentration known to be within the range (upper half)
of the concentration-response curve to ET in ex-vivo studies
using a myograph system.43,44
In conclusion, we definitively proved the existence of re-
fractoriness to ET in ocular vessels, at least in ex-vivo exper-
iments and, for the first time, established an approximate
time course of this interesting phenomenon. While the bio-
logical relevance of this finding needs to be established, it
should already be taken into account in studies involving
repeated ET applications.
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